The relationship between hepatoma-derived growth factor and prognosis in non-small cell lung cancer A systematic review and meta-analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Koh, Hyun Min | - |
dc.contributor.author | Hyun, Chang Lim | - |
dc.contributor.author | Jang, Bo Gun | - |
dc.contributor.author | Lee, Hyun Ju | - |
dc.date.accessioned | 2021-08-11T08:31:18Z | - |
dc.date.available | 2021-08-11T08:31:18Z | - |
dc.date.issued | 2020-12-18 | - |
dc.identifier.issn | 0025-7974 | - |
dc.identifier.issn | 1536-5964 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/2230 | - |
dc.description.abstract | Background: Hepatoma-derived growth factor (HDGF) promotes cancer progression and metastasis by interacting with vascular endothelial growth factor, thereby inducing epithelial-to-mesenchymal transition and angiogenesis. Recent studies have correlated increased HDGF levels with poor prognosis in various malignancies, including lung cancer. This meta-analysis systematically assessed the prognostic significance of HDGF expression in patients with non-small cell lung cancer (NSCLC). Methods: Eligible studies were identified by searching literature in PubMed, Embase, Scopus, and the Cochrane library until June 2020. The pooled hazard ratio (HR) or odds ratio (OR) with 95% confidence interval (CI) was determined to assess the relationship between HDGF expression and clinical outcome in patients with NSCLC. Results: The pooled HRs between high HDGF expression and clinical outcome were 2.20 (95% CI 1.75-2.76, P < .001) and 2.77 (95% CI 1.79-4.29, P < .001) for overall survival and disease-free survival, respectively. High HDGF expression was significantly correlated with a larger tumor size (OR 1.59, 95% CI 1.02-2.46, P = .040). Conclusion: HDGF expression is related to clinical outcome and may be a prognostic marker in patients with NSCLC. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Lippincott Williams & Wilkins Ltd. | - |
dc.title | The relationship between hepatoma-derived growth factor and prognosis in non-small cell lung cancer A systematic review and meta-analysis | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1097/MD.0000000000023837 | - |
dc.identifier.scopusid | 2-s2.0-85099116199 | - |
dc.identifier.wosid | 000612839600112 | - |
dc.identifier.bibliographicCitation | Medicine, v.99, no.51 | - |
dc.citation.title | Medicine | - |
dc.citation.volume | 99 | - |
dc.citation.number | 51 | - |
dc.type.docType | Review | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordAuthor | hepatoma-derived growth factor | - |
dc.subject.keywordAuthor | meta-analysis | - |
dc.subject.keywordAuthor | non-small cell lung cancer | - |
dc.subject.keywordAuthor | prognosis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.